Ztalmy
What Ztalmy is used for
Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Ztalmy
- Active substance
- ganaxolone
- Disease area
- Epileptic Syndromes; Spasms, Infantile
- Medicine group
- Other antiepileptics
- ATC code
- N03AX
- Marketing authorisation holder
- Marinus Pharmaceuticals Emerald Limited
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Ztalmy
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ztalmy used for?
Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.
What is the active substance in Ztalmy?
Ztalmy contains ganaxolone.
Who makes Ztalmy?
The EU marketing authorisation holder is Marinus Pharmaceuticals Emerald Limited.
Is Ztalmy an orphan medicine?
Yes. Ztalmy is designated an orphan medicine in the EU, for a rare disease (Epileptic Syndromes; Spasms, Infantile).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU